199 related articles for article (PubMed ID: 20944140)
1. Importance of miR-20a expression in prostate cancer tissue.
Pesta M; Klecka J; Kulda V; Topolcan O; Hora M; Eret V; Ludvikova M; Babjuk M; Novak K; Stolz J; Holubec L
Anticancer Res; 2010 Sep; 30(9):3579-83. PubMed ID: 20944140
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
3. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
5. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
6. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
7. Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.
Mohammadi Torbati P; Asadi F; Fard-Esfahani P
Asian Pac J Cancer Prev; 2019 May; 20(5):1453-1456. PubMed ID: 31127907
[TBL] [Abstract][Full Text] [Related]
8. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
9. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
10. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
[TBL] [Abstract][Full Text] [Related]
11. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
12. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
Hagman Z; Larne O; Edsjö A; Bjartell A; Ehrnström RA; Ulmert D; Lilja H; Ceder Y
Int J Cancer; 2010 Dec; 127(12):2768-76. PubMed ID: 21351256
[TBL] [Abstract][Full Text] [Related]
13. Expression of circulating microRNA-20a and let-7a in esophageal squamous cell carcinoma.
He FC; Meng WW; Qu YH; Zhou MX; He J; Lv P; Ming L
World J Gastroenterol; 2015 Apr; 21(15):4660-5. PubMed ID: 25914476
[TBL] [Abstract][Full Text] [Related]
14. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
16. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
Avgeris M; Stravodimos K; Fragoulis EG; Scorilas A
Br J Cancer; 2013 Jun; 108(12):2573-81. PubMed ID: 23703249
[TBL] [Abstract][Full Text] [Related]
17. Activin A regulates microRNAs and gene expression in LNCaP cells.
Ottley EC; Nicholson HD; Gold EJ
Prostate; 2016 Aug; 76(11):951-63. PubMed ID: 27018851
[TBL] [Abstract][Full Text] [Related]
18. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing.
Song C; Chen H; Wang T; Zhang W; Ru G; Lang J
Prostate; 2015 Apr; 75(5):500-16. PubMed ID: 25597612
[TBL] [Abstract][Full Text] [Related]
19. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
20. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
